Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Safety Study of Tenofovir Disoproxil Fumarate Tablets in Healthy Chinese Subjects
NCT07558967Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) and hepatitis B (HBV) (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Concentration-Time Curve from time 0 to time t at 72 hours and 1 more. Started Jun 2017; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07558967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558967.